Eisai Co Ltd (JP:4523)
:4523
Want to see JP:4523 full AI Analyst Report?
4523 Stock Chart & Stats
¥4891.00
-¥56.00(-1.27%)
At close: 4:00 PM EST
¥4891.00
-¥56.00(-1.27%)
Day’s Range― - ―
52-Week Range¥3,832.00 - ¥5,349.00
Previous CloseN/A
Volume1.20M
Average Volume (3M)1.34M
Market Cap
¥1.12T
Enterprise Value¥1.05T
Total Cash (Recent Filing)¥245.42B
Total Debt (Recent Filing)¥186.08B
Price to Earnings (P/E)35.6
Beta0.98
Next Earnings
Jul 31, 2026EPS Estimate
60.16Next Dividend Ex-DateN/A
Dividend Yield3.51%
Share Statistics
EPS (TTM)136.74
Shares Outstanding291,649,140
10 Day Avg. Volume1,231,250
30 Day Avg. Volume1,336,443
Financial Highlights & Ratios
PEG Ratio-2.16
Price to Book (P/B)1.53
Price to Sales (P/S)1.66
P/FCF Ratio29.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,000.00Price Target Upside-18.22% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)207.37
Revenue Forecast (FY)¥886.19B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid‑70s to ~80% gross margins indicate durable pricing power and favorable product economics. This margin base lets Eisai absorb R&D and commercialization costs, supporting long‑term operating resilience and the ability to invest in new drug development.
Conservative LeverageA low and improving debt profile gives Eisai financial flexibility to fund late‑stage trials, commercial launches, and partnerships without stressing solvency. Conservative leverage reduces refinancing and interest risk, supporting steady investment through multi‑year development cycles.
Diversified Partnerships & FranchisesEstablished collaborations (notably with Biogen) and a mix of neurology and oncology franchises create multiple durable revenue streams: product sales, milestones, and royalties. This diversification reduces single‑asset risk and supports sustained growth as demographics drive neurology demand.
Bears Say
Cash Flow VolatilityMeaningful year‑to‑year swings in operating and free cash flow increase execution risk: they can constrain R&D funding, limit strategic M&A or share returns, and require larger liquidity cushions. Volatility complicates multi‑year planning for drug development pipelines.
Eroding Net MarginsDeclining net margins signal margin pressure from cost, mix, or launch investments. Lower bottom‑line conversion of robust gross profits reduces internal cash generation and retained earnings available for reinvestment, weakening resilience against slower revenue growth.
Moderate Returns On EquityMid‑single digit ROE suggests limited capital efficiency relative to high‑growth pharma peers. Coupled with modest revenue growth (~4.6%) and negative recent EPS growth (~-16.6%), this constrains compound returns and may limit long‑term shareholder value creation.
Eisai Co News
4523 FAQ
What was Eisai Co Ltd’s price range in the past 12 months?
Eisai Co Ltd lowest stock price was ¥3832.00 and its highest was ¥5349.00 in the past 12 months.
What is Eisai Co Ltd’s market cap?
Eisai Co Ltd’s market cap is ¥1.12T.
When is Eisai Co Ltd’s upcoming earnings report date?
Eisai Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 63 days.
How were Eisai Co Ltd’s earnings last quarter?
Eisai Co Ltd released its earnings results on May 15, 2026. The company reported -¥11.53 earnings per share for the quarter, missing the consensus estimate of ¥12.424 by -¥23.954.
Is Eisai Co Ltd overvalued?
According to Wall Street analysts Eisai Co Ltd’s price is currently Overvalued.
Does Eisai Co Ltd pay dividends?
Eisai Co Ltd pays a Semiannually dividend of ¥80 which represents an annual dividend yield of 3.51%. See more information on Eisai Co Ltd dividends here
What is Eisai Co Ltd’s EPS estimate?
Eisai Co Ltd’s EPS estimate is 60.16.
How many shares outstanding does Eisai Co Ltd have?
Eisai Co Ltd has 291,649,140 shares outstanding.
What happened to Eisai Co Ltd’s price movement after its last earnings report?
Eisai Co Ltd reported an EPS of -¥11.53 in its last earnings report, missing expectations of ¥12.424. Following the earnings report the stock price went up 0.042%.
Which hedge fund is a major shareholder of Eisai Co Ltd?
Currently, no hedge funds are holding shares in JP:4523
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eisai Co Ltd
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
4523 Company Deck
4523 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance of their global brands and significant global expansion of LEQEMBI, contributing to positive revenue growth. However, challenges in controlling cost of sales, slower-than-expected U.S. market expansion, and concerns about competitive threats were notable downsides.View all JP:4523 earnings summaries4523 Stock 12 Month Forecast
Average Price Target
¥4,000.00
▼(-18.22% Downside)
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Kaken Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---